Migraine with Aura in Children and Adolescents (Under 18)

This protocol addresses migraine with aura in patients younger than 18 years — children and adolescents. The evidence base for preventive management in this age group differs substantially from adult practice, and the approach reflects those differences.

The effectiveness of pharmaceutical migraine prevention has not been unequivocally confirmed in children. Non-medical treatment should be preferentially used in this population.

Non-medical interventions are the preferred starting point. Where pharmacological prevention becomes necessary, there are specific agents with available paediatric evidence — but agent selection depends on the individual clinical picture.

The full structured regimen — including agent choice, sequencing, and clinical decision points — is available via the link below.